公开(公告)号：US12121578B2

公开(公告)日：2024-10-22

申请号：US17431833

申请日：2020-02-27

申请人： KM Biologics Co., Ltd.

发明人： Ryo Yamaue ,  Satoshi Kamakura ,  Mihoko Matsuo ,  Masaharu Torikai ,  Hiroaki Mori

IPC分类号： A61K39/155 ,  A61P31/14 ,  C12N7/00 ,  C12N15/62

CPC分类号： A61K39/155 ,  A61P31/14 ,  C12N7/00 ,  C12N15/62

摘要： A novel vaccine antigen for prevention of Respiratory Syncytial Virus (RSV) infection is created which surpasses conventional vaccines comprising as an antigen RSV F protein alone in view of efficacy and/or safety. A vaccine is prepared which comprises as an antigen a RSV F/G chimeric protein wherein a portion of RSV F protein as a basic structure is replaced with a whole or a portion of Conserved Central Domain sequence of RSV G protein or wherein a whole or a portion of Conserved Central Domain sequence of RSV G is added to the basic structure. As a result of assessment of both efficacy and safety, a vaccine comprising as an antigen the F/G chimeric protein of the present invention confirmed to be more excellent than a vaccine comprising as an antigen RSV F protein alone in view of efficacy and/or safety.